At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 201 enrolled
Drug / intervention
Celecoxib +1 moredrug
Likely dose
Celecoxib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Dec 12, 2008·Updated Feb 2, 2021
In Brief
A Phase 4 clinical trial evaluating Celecoxib and Naproxen for Arthritis, Juvenile Rheumatoid. Completed, enrolled 201 participants across 39 sites in 10 countries.
Detailed Summary
This Is A Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Juvenile Rheumatoid
CountriesChile, Costa Rica, Peru, Philippines, Russia, Serbia, South Africa, Switzerland, Ukraine, United States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartSep 2009
Primary CompletionDec 2012
TodayJul 2026
First PostedDec 12, 2008
Enrollment StartSep 1, 2009
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 17.6 years ago
Interventions
Celecoxibdrug
Celecoxib 50 mg or 100 mg PO BID for 6 weeks
Naproxendrug
Naproxen 7.5 mg/kg PO BID \[maximum of 500 mg BID\] for 6 weeks